BRITISH COLUMBIA, Canada--(BUSINESS WIRE)--InNexus Biotechnology Inc. (OTCBB: IXSBF) (TSX VENTURE: IXS) (http://www.ixsbio.com), a drug development company commercializing the next generation of monoclonal antibodies based on its technology, Dynamic Cross Linking (DXL™), announced today it has completed a brokered private placement for gross proceeds of $4,930,000 CDN at a purchase price of $0.25 per unit (the “Placement”).
